BlueWind Medical

BlueWind Medical is an innovative medical device company that aims to transform neuromodulation therapy for urgency incontinence. Founded in 2010 and headquartered in the United States, the company specializes in the biotechnology and healthcare industries. BlueWind Medical is focused on revolutionizing the treatment of urge urinary incontinence through its innovative miniature tibial neuromodulation (iTNM) device. This device is implanted near the ankle in a minimally invasive outpatient procedure, offering a patient-centric system that allows for therapy customization to enhance patient response. The company recently secured a significant $64.00M Series B investment on 09 May 2022, with the renowned medical products and technologies company, ConvaTec, participating as the lead investor. This substantial investment reflects growing confidence in BlueWind Medical's pioneering approach to neuromodulation therapy for urgency incontinence. Overall, BlueWind Medical's innovative approach, coupled with its recent substantial investment from a key player in the medical products and technologies sector, positions the company for significant growth and potential impact in transforming the treatment landscape for urge urinary incontinence.